Effect and Safety of ior® EPOCIM in patients with Non-Hodking Lymphoma treated with anthracyclines.

Phase 2

Suspended

• Conditions: Patients with Non-Hodking Lymphoma

• Registration Number: RPCEC00000096
• Lead Sponsor: Center of Molecular Immunology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06-11
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Suspended
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

.Patients who met the diagnostic criteria.
.Patients of either sex with age greater than or equal to 18 years.
.Patients who give informed consent to participate in writing.
.Patients with hemoglobin below 13 g/dl.

Exclusion Criteria

.Patients with uncontrolled hypertension.
.Patients with known risk or a history of venous or arterial thromboembolic disease.
.Severe cardiovascular disease:unstable angina,heart failure,aortic stenosis,endocarditis.
.Patients with poor acoustic window.
.Severe cerebrovascular disease. .Septic embolism.
.Chronic myeloproliferative diseases.
.Patients with known hypersensitivity to products derived from higher cells or hypersensitivity to human albumin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diastolic dysfunction (Yes/No).Dependent of the Deceleration time (DT),the value ejection/shortening (E/A)and the Isovolumic relaxation time (IVRT). Measurement time:in each cycle of chemotherapy ,4 weeks after finish chemotherapy , and every 4 months for a year after finish treatment . Septal and lateral speed by tissue doppler. Measurement time:in each cycle of chemotherapy ,4 weeks after finish chemotherapy , and every 4 months for a year after finish treatment . Septal and lateral E/e´relationship. Measurement time:in each cycle of chemotherapy ,4 weeks after finish chemotherapy , and every 4 months for a year after finish treatment .